Quantum BioPharma Hits Halfway Enrollment in MS Imaging Study
Quantum BioPharma reaches halfway enrollment in MS imaging study with MGH. Lucid-MS shows promise with robust signal in acute MS lesions. Read more.
This milestone matters because multiple sclerosis is a debilitating disease affecting millions, and current treatments have limitations. Lucid-MS could offer a new therapeutic option if proven effective. The halfway enrollment indicates progress in clinical development, bringing us closer to potential new treatments for MS patients.